Angelini Pharma invests in Argobio, an innovative start-up incubator
Angelini Pharma keeps investing in research and innovation and announces its contribution to Argobio, a French start-up incubator dedicated to life sciences.
Science
-
-
Generalized Anxiety Disorder: what are we really talking about?
In common parlance, the term “anxiety” is often misused. But it is a reaction that seriously interferes with the psycho-intellectual performance, preventing people to live a normal life
-
Depression: the critical postmenopausal period
The cessation of fertility can mark the beginning of a period of mental fragility for women, especially in the presence of other psycho-physical problems or stressors.
-
From fear to anger: the dominant feelings during the COVID-19 pandemic
An analysis of some 20,000 messages left on Twitter around the world documents a change in the state of mind of the general public.
-
Psychological disorders are the second health concern in Europe
Agnese Cattaneo, Chief Medical Officer Angelini Pharma, talks about a recent research on the awareness about mental health and the impact of the pandemic.
-
Schizophrenia
For centuries schizophrenia has been considered the psychiatric disease par excellence, due to its conspicuous manifestations (if not properly treated) and the impossibility of interacting with the people affected, and making them “reason” according to conventional criteria.
-
Persistent depressive disorder
Described as a depressive disorder, persistent depressive disorder is a more chronic form of depression: its diagnosis can be made when the mood disorder continues for at least 2 years in adults, or 1 year in children.
